{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:02:09Z","timestamp":1792796529353,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P 35292"],"award-info":[{"award-number":["P 35292"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["W 1224"],"award-info":[{"award-number":["W 1224"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P 31920"],"award-info":[{"award-number":["P 31920"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ISIDORe","award":["101046133"],"award-info":[{"award-number":["101046133"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Newly emerging SARS-CoV-2 variants of concern (VOCs) continue to drive COVID-19 waves and are typically associated with immune escape and increased resistance to current therapeutics including monoclonal antibodies. By contrast, VOCs still display strong binding to the host cell receptor ACE2. Consistent with these properties, we have now found that a soluble ACE2-Fc decoy produced in glycoengineered plants effectively neutralizes different SARS-CoV-2 isolates and exhibits even increased potency against VOCs as compared to an ancestral virus strain. In a golden Syrian hamster model, therapeutic intranasal delivery of ACE2-Fc effectively reduced weight loss and SARS-CoV-2 replication in the lungs when administered 24\u00a0h post-inoculation. This protective effect was not observed upon treatment of the infected animals with a non-binding ACE2-Fc mutant, demonstrating that the plant-derived ACE2-Fc decoy interferes specifically with the attachment of the virus to host cells. The results obtained provide support for further development of decoy-based antiviral approaches by plant molecular pharming.<\/jats:p>","DOI":"10.1038\/s41598-025-95494-w","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T13:39:22Z","timestamp":1743773962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An ACE2-Fc decoy produced in glycoengineered plants neutralizes ancestral and newly emerging SARS-CoV-2 variants and demonstrates therapeutic efficacy in hamsters"],"prefix":"10.1038","volume":"15","author":[{"given":"Esther","family":"F\u00f6derl-H\u00f6benreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Hofacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus F.","family":"Kienzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Castilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Tarr\u00e9s-Freixas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Cantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f2nica","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Lorca-Or\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Usai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Segal\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia","family":"Vergara-Alert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Zatloukal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"95494_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101349","volume":"62","author":"AZ Mykytyn","year":"2023","unstructured":"Mykytyn, A. Z., Fouchier, R. A. & Haagmans, B. L. Antigenic evolution of SARS coronavirus 2. Curr. Opin. Virol. 62, 101349. https:\/\/doi.org\/10.1016\/j.coviro.2023.101349 (2023).","journal-title":"Curr. Opin. Virol."},{"key":"95494_CR2","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1038\/s41467-022-31556-1","volume":"13","author":"M Bekliz","year":"2022","unstructured":"Bekliz, M. et al. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nat. Commun. 13, 3840. https:\/\/doi.org\/10.1038\/s41467-022-31556-1 (2022).","journal-title":"Nat. Commun."},{"key":"95494_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41579-023-01001-1","volume":"22","author":"EA Meyerowitz","year":"2024","unstructured":"Meyerowitz, E. A., Scott, J., Richterman, A., Male, V. & Cevik, M. Clinical course and management of COVID-19 in the era of widespread population immunity. Nat. Rev. Microbiol. 22, 75\u201388. https:\/\/doi.org\/10.1038\/s41579-023-01001-1 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"95494_CR4","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.it.2020.10.004","volume":"41","author":"AG Harrison","year":"2020","unstructured":"Harrison, A. G., Lin, T. & Wang, P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 41, 1100\u20131115. https:\/\/doi.org\/10.1016\/j.it.2020.10.004 (2020).","journal-title":"Trends Immunol."},{"key":"95494_CR5","doi-asserted-by":"publisher","first-page":"e9610","DOI":"10.15252\/msb.20209610","volume":"16","author":"F Hikmet","year":"2020","unstructured":"Hikmet, F. et al. The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 16, e9610. https:\/\/doi.org\/10.15252\/msb.20209610 (2020).","journal-title":"Mol. Syst. Biol."},{"key":"95494_CR6","doi-asserted-by":"publisher","first-page":"111903","DOI":"10.1016\/j.celrep.2022.111903","volume":"42","author":"J Huo","year":"2023","unstructured":"Huo, J. et al. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA2.75. Cell Rep 42, 111903. https:\/\/doi.org\/10.1016\/j.celrep.2022.111903 (2023).","journal-title":"Cell Rep"},{"key":"95494_CR7","doi-asserted-by":"publisher","first-page":"e15230","DOI":"10.15252\/emmm.202115230","volume":"14","author":"V Monteil","year":"2022","unstructured":"Monteil, V. et al. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. EMBO Mol Med 14, e15230. https:\/\/doi.org\/10.15252\/emmm.202115230 (2022).","journal-title":"EMBO Mol Med"},{"key":"95494_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2024.108403","volume":"75","author":"JF Buyel","year":"2024","unstructured":"Buyel, J. F. Towards a seamless product and process development workflow for recombinant proteins produced by plant molecular farming. Biotechnol. Adv. 75, 108403. https:\/\/doi.org\/10.1016\/j.biotechadv.2024.108403 (2024).","journal-title":"Biotechnol. Adv."},{"key":"95494_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2023.108197","volume":"67","author":"R Strasser","year":"2023","unstructured":"Strasser, R. Plant glycoengineering for designing next-generation vaccines and therapeutic proteins. Biotechnol. Adv. 67, 108197. https:\/\/doi.org\/10.1016\/j.biotechadv.2023.108197 (2023).","journal-title":"Biotechnol. Adv."},{"key":"95494_CR10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/imm.13481","volume":"166","author":"B Wolf","year":"2022","unstructured":"Wolf, B. et al. Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity. Immunology 166, 380\u2013407. https:\/\/doi.org\/10.1111\/imm.13481 (2022).","journal-title":"Immunology"},{"key":"95494_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.863118","volume":"10","author":"K Dammen-Brower","year":"2022","unstructured":"Dammen-Brower, K. et al. Strategies for glycoengineering therapeutic proteins. Front. Chem. 10, 863118. https:\/\/doi.org\/10.3389\/fchem.2022.863118 (2022).","journal-title":"Front. Chem."},{"key":"95494_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","volume":"29","author":"WR Strohl","year":"2015","unstructured":"Strohl, W. R. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29, 215\u2013239. https:\/\/doi.org\/10.1007\/s40259-015-0133-6 (2015).","journal-title":"BioDrugs"},{"key":"95494_CR13","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1074\/jbc.M117.817064","volume":"293","author":"J Chia","year":"2018","unstructured":"Chia, J. et al. Half-life\u2013extended recombinant coagulation factor IX\u2013albumin fusion protein is recycled via the FcRn-mediated pathway. J. Biol. Chem. 293, 6363\u20136373. https:\/\/doi.org\/10.1074\/jbc.M117.817064 (2018).","journal-title":"J. Biol. Chem."},{"key":"95494_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/emmm.201201379","volume":"4","author":"DM Czajkowsky","year":"2012","unstructured":"Czajkowsky, D. M., Hu, J., Shao, Z. & Pleass, R. J. Fc-fusion proteins: New developments and future perspectives. EMBO Mol. Med. 4, 1015\u20131028. https:\/\/doi.org\/10.1002\/emmm.201201379 (2012).","journal-title":"EMBO Mol. Med."},{"key":"95494_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","volume":"23","author":"A Zhang","year":"2023","unstructured":"Zhang, A. et al. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat. Rev. Immunol. 23, 381\u2013396. https:\/\/doi.org\/10.1038\/s41577-022-00813-1 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"95494_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00685-21","volume":"95","author":"M Ferrari","year":"2021","unstructured":"Ferrari, M. et al. Characterization of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV-2 variants. J. Virol. 95, e0068521. https:\/\/doi.org\/10.1128\/JVI.00685-21 (2021).","journal-title":"J. Virol."},{"key":"95494_CR17","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.73641","volume":"10","author":"T Capraz","year":"2021","unstructured":"Capraz, T. et al. Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. Elife 10, e73641. https:\/\/doi.org\/10.7554\/eLife.73641 (2021).","journal-title":"Elife"},{"key":"95494_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01283-20","volume":"94","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. SARS-CoV-2 and three related coronaviruses utilize multiple ACE2 orthologs and are potently blocked by an improved ACE2-Ig. J. Virol. 94, e0128320. https:\/\/doi.org\/10.1128\/JVI.01283-20 (2020).","journal-title":"J. Virol."},{"key":"95494_CR19","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s42003-022-04193-z","volume":"5","author":"HL Svilenov","year":"2022","unstructured":"Svilenov, H. L. et al. Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants. Commun. Biol. 5, 1237. https:\/\/doi.org\/10.1038\/s42003-022-04193-z (2022).","journal-title":"Commun. Biol."},{"key":"95494_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.kint.2018.01.029","volume":"94","author":"P Liu","year":"2018","unstructured":"Liu, P. et al. Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney Int. 94, 114\u2013125. https:\/\/doi.org\/10.1016\/j.kint.2018.01.029 (2018).","journal-title":"Kidney Int."},{"key":"95494_CR21","doi-asserted-by":"publisher","first-page":"2000566","DOI":"10.1002\/biot.202000566","volume":"16","author":"A Castilho","year":"2021","unstructured":"Castilho, A. et al. Generation of enzymatically competent SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered Nicotiana benthamiana. Biotechnol. J. 16, 2000566. https:\/\/doi.org\/10.1002\/biot.202000566 (2021).","journal-title":"Biotechnol. J."},{"key":"95494_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41467-022-28354-0","volume":"13","author":"R Abdelnabi","year":"2022","unstructured":"Abdelnabi, R. et al. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nat. Commun. 13, 719. https:\/\/doi.org\/10.1038\/s41467-022-28354-0 (2022).","journal-title":"Nat. Commun."},{"key":"95494_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41421-022-00431-0","volume":"8","author":"L Li","year":"2022","unstructured":"Li, L. et al. Broader-species receptor binding and structural bases of Omicron SARS-CoV-2 to both mouse and palm-civet ACE2s. Cell Discov. 8, 65. https:\/\/doi.org\/10.1038\/s41421-022-00431-0 (2022).","journal-title":"Cell Discov."},{"key":"95494_CR24","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","volume":"22","author":"D Focosi","year":"2022","unstructured":"Focosi, D. et al. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect. Dis. 22, e311\u2013e326. https:\/\/doi.org\/10.1016\/S1473-3099(22)00311-5 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"95494_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41579-022-00841-7","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162\u2013177. https:\/\/doi.org\/10.1038\/s41579-022-00841-7 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"95494_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41467-022-28528-w","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. Nat. Commun. 13, 871. https:\/\/doi.org\/10.1038\/s41467-022-28528-w (2022).","journal-title":"Nat. Commun."},{"key":"95494_CR27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/jcc.27025","volume":"44","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. Binding of human ACE2 and RBD of Omicron enhanced by unique interaction patterns among SARS-CoV-2 variants of concern. J. Comput. Chem. 44, 594\u2013601. https:\/\/doi.org\/10.1002\/jcc.27025 (2023).","journal-title":"J. Comput. Chem."},{"key":"95494_CR28","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838. https:\/\/doi.org\/10.1038\/s41586-020-2342-5 (2020).","journal-title":"Nature"},{"key":"95494_CR29","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl. Acad. Sci. 117, 16587\u201316595. https:\/\/doi.org\/10.1073\/pnas.2009799117 (2020).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"95494_CR30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.medj.2022.03.004","volume":"3","author":"K McMahan","year":"2022","unstructured":"McMahan, K. et al. Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. Med 3, 262-268.e4. https:\/\/doi.org\/10.1016\/j.medj.2022.03.004 (2022).","journal-title":"Med"},{"key":"95494_CR31","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1038\/s41467-023-40933-3","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants. Nat. Commun. 14, 5191. https:\/\/doi.org\/10.1038\/s41467-023-40933-3 (2023).","journal-title":"Nat. Commun."},{"key":"95494_CR32","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1038\/s41467-021-24013-y","volume":"12","author":"Y Higuchi","year":"2021","unstructured":"Higuchi, Y. et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat. Commun. 12, 3802. https:\/\/doi.org\/10.1038\/s41467-021-24013-y (2021).","journal-title":"Nat. Commun."},{"key":"95494_CR33","doi-asserted-by":"publisher","first-page":"eabn7737","DOI":"10.1126\/scitranslmed.abn7737","volume":"14","author":"N Ikemura","year":"2022","unstructured":"Ikemura, N. et al. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. Sci. Transl. Med. 14, eabn7737. https:\/\/doi.org\/10.1126\/scitranslmed.abn7737 (2022).","journal-title":"Sci. Transl. Med."},{"key":"95494_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq6527","author":"JA Torchia","year":"2022","unstructured":"Torchia, J. A. et al. Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abq6527 (2022).","journal-title":"Sci. Adv."},{"key":"95494_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.20411\/pai.v7i1.491","volume":"7","author":"E Merigeon","year":"2022","unstructured":"Merigeon, E. et al. An ACE2-IgG4 Fc fusion protein demonstrates strong binding to all tested SARS-CoV-2 variants and reduced lung inflammation in animal models of SARS-CoV-2 and influenza. Pathog. Immun. 7, 104\u2013121. https:\/\/doi.org\/10.20411\/pai.v7i1.491 (2022).","journal-title":"Pathog. Immun."},{"key":"95494_CR36","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/v15040964","volume":"15","author":"C-M Kim","year":"2023","unstructured":"Kim, C.-M. et al. Efficacy of plant-made human recombinant ACE2 against COVID-19 in a golden Syrian hamster model. Viruses 15, 964. https:\/\/doi.org\/10.3390\/v15040964 (2023).","journal-title":"Viruses"},{"key":"95494_CR37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s42003-023-04860-9","volume":"6","author":"B Havranek","year":"2023","unstructured":"Havranek, B. et al. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo. Commun. Biol. 6, 513. https:\/\/doi.org\/10.1038\/s42003-023-04860-9 (2023).","journal-title":"Commun. Biol."},{"key":"95494_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jssc.202000765","volume":"44","author":"BL Duivelshof","year":"2021","unstructured":"Duivelshof, B. L. et al. Therapeutic Fc-fusion proteins: Current analytical strategies. J. Sep. Sci. 44, 35\u201362. https:\/\/doi.org\/10.1002\/jssc.202000765 (2021).","journal-title":"J. Sep. Sci."},{"key":"95494_CR39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41592-022-01447-w","volume":"19","author":"H Chu","year":"2022","unstructured":"Chu, H., Chan, J.F.-W. & Yuen, K.-Y. Animal models in SARS-CoV-2 research. Nat. Methods 19, 392\u2013394. https:\/\/doi.org\/10.1038\/s41592-022-01447-w (2022).","journal-title":"Nat. Methods"},{"key":"95494_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111359","volume":"40","author":"S Liu","year":"2022","unstructured":"Liu, S., Selvaraj, P., Sangare, K., Luan, B. & Wang, T. T. Spike protein-independent attenuation of SARS-CoV-2 omicron variant in laboratory mice. Cell Rep. 40, 111359. https:\/\/doi.org\/10.1016\/j.celrep.2022.111359 (2022).","journal-title":"Cell Rep."},{"key":"95494_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.840757","volume":"13","author":"F Tarr\u00e9s-Freixas","year":"2022","unstructured":"Tarr\u00e9s-Freixas, F. et al. Heterogeneous infectivity and pathogenesis of SARS-CoV-2 variants beta, delta and omicron in transgenic K18-hACE2 and wildtype mice. Front. Microbiol. 13, 840757. https:\/\/doi.org\/10.3389\/fmicb.2022.840757 (2022).","journal-title":"Front. Microbiol."},{"key":"95494_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2020.604663","volume":"11","author":"K Siriwattananon","year":"2021","unstructured":"Siriwattananon, K. et al. Development of plant-produced recombinant ACE2-Fc fusion protein as a potential therapeutic agent against SARS-CoV-2. Front. Plant Sci. 11, 604663. https:\/\/doi.org\/10.3389\/fpls.2020.604663 (2021).","journal-title":"Front. Plant Sci."},{"key":"95494_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2021.742875","volume":"12","author":"T Mamedov","year":"2021","unstructured":"Mamedov, T. et al. Soluble human angiotensin- converting enzyme 2 as a potential therapeutic tool for COVID-19 is produced at high levels in Nicotiana benthamiana plant with potent anti-SARS-CoV-2 activity. Front. Plant. Sci. 12, 742875. https:\/\/doi.org\/10.3389\/fpls.2021.742875 (2021).","journal-title":"Front. Plant. Sci."},{"key":"95494_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202300319","volume":"19","author":"S Lim","year":"2024","unstructured":"Lim, S. et al. Enhanced binding and inhibition of SARS-CoV-2 by a plant-derived ACE2 protein containing a fused mu tailpiece. Biotechnol. J. 19, e2300319. https:\/\/doi.org\/10.1002\/biot.202300319 (2024).","journal-title":"Biotechnol. J."},{"key":"95494_CR45","doi-asserted-by":"publisher","first-page":"1180044","DOI":"10.3389\/fbioe.2023.1180044","volume":"11","author":"S Izadi","year":"2023","unstructured":"Izadi, S. et al. In planta deglycosylation improves the SARS-CoV-2 neutralization activity of recombinant ACE2-Fc. Front. Bioeng. Biotechnol. 11, 1180044. https:\/\/doi.org\/10.3389\/fbioe.2023.1180044 (2023).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"95494_CR46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1467-7652.2008.00330.x","volume":"6","author":"R Strasser","year":"2008","unstructured":"Strasser, R. et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N -glycan structure. Plant Biotechnol. J. 6, 392\u2013402. https:\/\/doi.org\/10.1111\/j.1467-7652.2008.00330.x (2008).","journal-title":"Plant Biotechnol. J."},{"key":"95494_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202100422","volume":"17","author":"M Klausberger","year":"2022","unstructured":"Klausberger, M. et al. Designed SARS-CoV-2 receptor binding domain variants form stable monomers. Biotechnol. J. 17, e2100422. https:\/\/doi.org\/10.1002\/biot.202100422 (2022).","journal-title":"Biotechnol. J."},{"key":"95494_CR48","doi-asserted-by":"publisher","first-page":"14838","DOI":"10.1074\/jbc.M200581200","volume":"277","author":"C Vickers","year":"2002","unstructured":"Vickers, C. et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838\u201314843. https:\/\/doi.org\/10.1074\/jbc.M200581200 (2002).","journal-title":"J. Biol. Chem."},{"key":"95494_CR49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12250-020-00230-5","volume":"36","author":"C Lei","year":"2021","unstructured":"Lei, C., Yang, J., Hu, J. & Sun, X. On the calculation of TCID50 for quantitation of virus infectivity. Virol. Sin. 36, 141\u2013144. https:\/\/doi.org\/10.1007\/s12250-020-00230-5 (2021).","journal-title":"Virol. Sin."},{"key":"95494_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104926","volume":"25","author":"M Zacharias","year":"2022","unstructured":"Zacharias, M. et al. Host and microbiome features of secondary infections in lethal covid-19. IScience 25, 104926. https:\/\/doi.org\/10.1016\/j.isci.2022.104926 (2022).","journal-title":"IScience"},{"key":"95494_CR51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12985-021-01587-z","volume":"18","author":"K Yan","year":"2021","unstructured":"Yan, K., Rawle, D. J., Le, T. T. & Suhrbier, A. Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytomorbidity-associated false positives. Virol. J. 18, 123. https:\/\/doi.org\/10.1186\/s12985-021-01587-z (2021).","journal-title":"Virol. J."},{"key":"95494_CR52","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/22221751.2021.1913974","volume":"10","author":"M Brustolin","year":"2021","unstructured":"Brustolin, M. et al. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. Emerg. Microbes Infect. 10, 797\u2013809. https:\/\/doi.org\/10.1080\/22221751.2021.1913974 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"95494_CR53","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.3390\/molecules28062612","volume":"28","author":"W J\u00e4ger","year":"2023","unstructured":"J\u00e4ger, W. et al. Identification of a synthetic polyhydroxyphenolic resveratrol analogue, 3,3\u2032,4,4\u2032,5,5\u2032-hexahydroxy-trans-stilbene with anti-SARS-CoV-2 activity. Molecules 28, 2612. https:\/\/doi.org\/10.3390\/molecules28062612 (2023).","journal-title":"Molecules"},{"key":"95494_CR54","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1038\/s41467-020-19684-y","volume":"11","author":"R Boudewijns","year":"2020","unstructured":"Boudewijns, R. et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 11, 5838. https:\/\/doi.org\/10.1038\/s41467-020-19684-y (2020).","journal-title":"Nat. Commun."},{"key":"95494_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109400","volume":"36","author":"TL Bricker","year":"2021","unstructured":"Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400. https:\/\/doi.org\/10.1016\/j.celrep.2021.109400 (2021).","journal-title":"Cell Rep."},{"key":"95494_CR56","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3201\/eid2608.201246","volume":"26","author":"X Lu","year":"2020","unstructured":"Lu, X. et al. US CDC real-time reverse transcription PCR Panel for detection of severe acute respiratory syndrome coronavirus 2. Emerg. Infect. Dis. 26, 1654\u20131665. https:\/\/doi.org\/10.3201\/eid2608.201246 (2020).","journal-title":"Emerg. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95494-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95494-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95494-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T07:55:23Z","timestamp":1744271723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95494-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95494"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95494-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.Z. is co-founder and CEO of Zatloukal Innovations GmbH. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11307"}}